Work

A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial

Year: 2020
Type: article
Abstract: Background In the absence of a well-established therapeutic approach, patients with irritable bowel syndrome seek alternative strategies such as probiotics. Aims The current trial named LAPIBSS aimed to demonstrate the efficacy of a 2-strain mixture of Lactobacillus acidophilus to improve irritable bowel syndrome symptoms. Methods Eighty patients diagnosed for irritable bowel syndrome were recruited to a multicentre, double-blinded, in parallel groups, placebo-controlled, randomized clinical trial. Patients were provided with a daily dose of two capsules containing either probiotics (5 × 10 9 cfu/capsule) or placebo for 8 weeks. The primary outcome was abdominal pain score assessed with a 100-mm visual analogue scale. Secondary outcomes included scores of bloating, flatus and rumbling assessed with a 100-mm visual analogue scale, a composite score and bowel habits. Results Abdominal pain score was significantly improved in both groups at weeks 4 and 8 ( P < 0.0001), but no significant differences were found between groups at week 8 (19.0 ± 2.5 vs 25.1 ± 2.6, respectively; LS Means differences = 6.0 ± 3.2; P = 0.06). Significant differences between groups were observed for flatus score at week 4 ( P = 0.04) and week 8 ( P = 0.03) and composite score ( P = 0.04) at week 8. Conclusions The consumption of the 2-strain mixture of L. acidophilus over 8 weeks is safe and decreases significantly flatus and composite scores. Trial registration number EudraCT No 2008 A00844-51.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,000
Funder: Bpifrance
OpenAlex ID: W2999464446
FWCI: 3.833
Cites: 31
Cited by: 45
Related to: 10